Top Markets
#1 Cross Cross +12.78%
#2 Casper Network Casper Network +11.85%
#3 Gama Token Gama Token +9.13%
#4 龙虾 (Lobster) 龙虾 (Lobster) +5.14%
#5 Perle Perle +4.54%
#6 Berachain Berachain +4.52%
#7 Akedo Akedo +4.17%
#8 Humanity Humanity +3.77%
#9 The Innovation Game The Innovation Game +3.74%
#10 Palladium Network Palladium Network +3.67%
Coin of the day
Cross Cross
설정
언어
한국어
통화
USD
테마
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
주식 순위 #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
주가
$1.73
마지막 동기화: 2025-06-17
시가총액
$2.55M
변동 (1일)
-0.29%
변동 (1년)
0.00%
국가
US
거래 Eiger BioPharmaceuticals, Inc. (EIGR)

카테고리

Healthcare
Eiger BioPharmaceuticals, Inc. (EIGR)의 수익
2026 기준 수익 TTM: 0
Eiger BioPharmaceuticals, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Eiger BioPharmaceuticals, Inc.의 수익 기록 (2026 ~ 2026)
연말 수익
연도 수익 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE